Medicine and Dentistry
Clinical Trial
100%
Nephropathy
100%
Diabetes
100%
Canagliflozin
100%
Diseases
58%
Diabetic Nephropathy
58%
Patient
57%
Kidney
57%
COVID-19
50%
Extracorporeal
50%
Blood Purification
50%
Acute Pancreatitis
50%
Sodium Glucose Cotransporter 2 Inhibitor
50%
Apoplexy
50%
Age
50%
Meta-Analysis
50%
Cardiovascular Effect
50%
Randomized Clinical Trial
50%
Post-Hoc Analysis
50%
Atrial Fibrillation
50%
Severe Acute Respiratory Syndrome Coronavirus 2
37%
Acute Kidney Injury
28%
Cardiovascular System
27%
Multiple Organ Dysfunction Syndrome
26%
Immune Response
25%
Inpatient
19%
Hazard Ratio
19%
Development
16%
Death
15%
Glomerular Filtration Rate
15%
Complication
14%
Therapeutic Procedure
12%
Immune Dysregulation
12%
Acute Respiratory Distress Syndrome
12%
Antivirus Agent
12%
Respiratory Disease
12%
Infection
12%
Emergency
12%
Blood
12%
Coronavirinae
12%
Apheresis
12%
Combination Therapy
12%
Age Groups
12%
Placebo
11%
Cerebral Hemorrhage
11%
Evaluation Study
8%
Female
8%
Serum
8%
Creatinine
8%
Renal Failure
8%
Nursing and Health Professions
Clinical Evaluation
100%
Diabetes Mellitus
100%
Canagliflozin
100%
Kidney Disease
100%
Diabetic Nephropathy
58%
Sodium Glucose Cotransporter 2 Inhibitor
50%
Meta Analysis
50%
Atrial Fibrillation
50%
Post Hoc Analysis
50%
Hazard Ratio
31%
Estimated Glomerular Filtration Rate
25%
Brain Hemorrhage
18%
Placebo
16%
Patient
12%
Non Insulin Dependent Diabetes Mellitus
12%
Chronic Kidney Failure
12%
Brain Ischemia
12%
Creatinine Blood Level
8%
Kidney Failure
8%
Death
8%
Evaluation Study
8%
Electric Potential
6%
Marker
6%
Albuminuria
6%
Protection
6%
Follow up
6%
Pharmacology, Toxicology and Pharmaceutical Science
Diabetes Mellitus
57%
Hyperkalemia
50%
Canagliflozin
50%
Kidney Disease
50%
Sodium Zirconium Cyclosilicate
42%
Potassium
35%
Chronic Kidney Failure
14%
Heart Failure
14%
Aldosterone
14%
Angiotensin
14%
Renin
14%
Kidney Failure
8%
Diabetic Nephropathy
8%
Death
8%
Creatinine
8%
Randomized Clinical Trial
7%
Drug
7%
Pharmacokinetics
7%
Mortality
7%
Sudden Death
7%
Resin
7%
Heart Arrhythmia
7%
Patiromer
7%
Adverse Event
7%
Potassium Sparing Diuretic Agent
7%
Clinical Trial
7%